Antiphospholipid syndrome is an autoimmune disorder characterized by arterial or venous thrombosis, recurrent first-trimester pregnancy loss, and multiple additional clinical manifestations. We describe a man with severe atherosclerotic basilar artery stenosis and superimposed in situ thrombus who was found to have antiphospholipid syndrome.
CASE REPORT
A 44-year-old male heavy smoker presented to the emergency department following the acute onset of left-sided weakness while at work. Th e patient had no history of hypertension, hyperlipidemia, diabetes, or obesity. No personal or family history of deep venous thrombosis or hypercoagulable disorder was present. Noncontrast head computed tomography (CT) and CT angiography revealed severe distal basilar artery stenosis (Figure 1 ). Emergent intravenously administered tissue plasminogen activator (tPA) thrombolytic therapy provided brief improvement followed by worsening left-sided weakness. Digital subtraction angiography confi rmed the CT angiography fi ndings. Intraarterial tPA was administered into the region of severe atherosclerotic stenosis and presumed in situ thrombus approximately 3 hours after intravenous tPA with slight improvement in the size of the lumen and contrast fl ow. Th e following day, magnetic resonance imaging (MRI) revealed acute ischemic change within the rostral pons and midbrain (Figure 2) . Two days after admission, the patient's neurologic status began to decline further, with interval loss of right upper and lower extremity motor function as well as severely dysarthric bulbar speech. Emergent repeat digital subtraction angiography with basilar artery endovascular stenting was performed ( Figure 3) . A hypercoagulability clinical evaluation revealed signifi cantly elevated anticardiolipin antibodies (aCL) (IgG 31.9, IgM 66.2) and positive lupus-like anticoagulant. Th e patient received systemic anticoagulation with heparin followed by transition to warfarin. Aspirin was also initiated. Th e patient required tracheostomy and percutaneous gastrostomy. His right-sided weakness improved soon after stenting, and his dysarthric speech improved more gradually. Th e patient tolerated decannulation of his tracheostomy prior to discharge and was tolerating a dysphagia diet per speech therapy recommendations. He was discharged to a skilled nursing facility with a residual neurologic defi cit of 4/5 right upper and lower extremity strength, 2/5 left upper extremity strength, and 0/5 left lower extremity strength.
DISCUSSION
Antiphospholipid syndrome (APS) is associated with persistently positive antiphospholipid antibodies (aPL), most commonly aCL and lupus-like anticoagulant (1). In the absence of an underlying connective tissue disorder, the syndrome is referred to as primary APS, while secondary APS is most commonly seen associated with systemic lupus erythematosus. Diverse neurological manifestations of APS include cerebrovascular disease (stroke, transient ischemic attack, and venous thrombosis) in addition to a multiple sclerosis-like syndrome, seizures, migraine headaches, and cognitive dysfunction (1, 2). Th ese symptoms are thought to refl ect manifestations of hypercoagulability-induced ischemia of neural tissue and possibly direct actions of aPL.
Experimental and clinical data have suggested an association of APS with atherosclerosis. Endothelial dysfunction, oxidative stress, platelet activation, and increased cell adhesion molecules are common to both diseases (3). Premature atherosclerosis may be the fi rst clinical manifestation of APS, and in a case such as this where age-accelerated atherosclerosis is seen with superimposed thrombosis and subsequent rethrombosis, a hypercoagulable state such as APS should be considered. In a low-density lipoprotein receptor knockout mouse model with aCL induced by immunization with human aCL from an APS patient, enhanced atherogenesis has been observed (3). Endothelial dysfunction has been demonstrated using positron emission tomography in patients with APS (3) .
Th e treatment of patients with APS and thrombotic events is based on guidelines for venous thrombosis and ischemic Basilar artery thrombosis in the setting of antiphospholipid syndrome Amin F. Saad, MD, Larry T. Nickell, MD, R. Evans Heithaus, MD, Sadat A. Shamim, MD, Michael J. Opatowsky, MD, MBA, and Kennith F. Layton, MD, MS stroke. Th e Antiphospholipid Antibodies and Stroke Study showed no diff erence between aspirin therapy and warfarin; however, in patients with severe thrombotic central nervous system manifestations, long-term treatment with warfarin has been recommended (1). Statins may be benefi cial in the reduction of aPL-induced endothelial cell activation and intracellular signaling (1, 2) .
Basilar thrombosis is a neurologically devastating condition, with considerable mortality as well as frequently devastating neurologic outcomes to include the so-called "locked in" syndrome. Complete recanalization can be achieved in about 60% of patients. Survival rates in patients undergoing thrombolysis alone range from only 30% to 60% (4). Revascularization is strongly linked to improved clinical outcomes (5) . Thrombolysis alone may be unable to achieve revascularization particularly in the setting of underlying atherosclerosis, and a residual highgrade stenosis may increase the risk of reocclusion (6) . In the series reported by Shi et al, successful stent placement was achieved in 90% of patients following intraarterial thrombolysis (6) . Stenting in the setting of APL has not been previously described. 
